S
Sera Economics
← US Companies

GSK plc

GSK · NYSE, OTC · CIK 0001131399

SIC 2834

Pharmaceutical Preparations

Category

Chemicals

Entity

other

Incorp.

X0

Fiscal Y/E

-

Source: SEC EDGAR · All filings on SEC →

Investment Indicators

$49.83

-0.58 (-1.15%)

Open

$50.65

High

$50.92

Low

$49.71

Prev Close

$50.41

Volume

3,335,560

Quote as of: 2026-05-11

Financial Statements

No XBRL data — applies to ETFs and some funds

📄 SEC Filings

6-K

Foreign Current

COLLABORATION WITH CTTQ FOR BEPIROVIRSEN

2026-05-11

Open →

6-K

Foreign Current

GSK - FINAL TRANCHE OF SHARE BUYBACK PROGRAMME

2026-05-11

Open →

6-K

Foreign Current

RESULT OF AGM

2026-05-06

Open →

6-K

Foreign Current

DIRECTOR/PDMR SHAREHOLDING

2026-05-05

Open →

6-K

Foreign Current

TOTAL VOTING RIGHTS

2026-05-01

Open →

6-K

Foreign Current

HOLDING(S) IN COMPANY

2026-05-01

Open →

6-K

Foreign Current

DIRECTOR/PDMR SHAREHOLDING

2026-04-29

Open →

6-K

Foreign Current

1ST QUARTER RESULTS

2026-04-29

Open →

6-K

Foreign Current

DIRECTOR/PDMR SHAREHOLDING

2026-04-28

Open →

6-K

Foreign Current

BEPIROVIRSEN PRIORITY REVIEW US FILING ACCEPTANCE

2026-04-28

Open →

6-K

Foreign Current

EFIMOSFERMIN GRANTED US/EU REGULATORY DESIGNATIONS

2026-04-27

Open →

6-K

Foreign Current

TESARO UPDATE ON ANAPTYSBIO INC. LITIGATION

2026-04-27

Open →

6-K

Foreign Current

DIRECTOR/PDMR SHAREHOLDING

2026-04-24

Open →

6-K

Foreign Current

TRANSACTION IN OWN SHARES

2026-04-23

Open →

6-K

Foreign Current

TRANSACTION IN OWN SHARES

2026-04-22

Open →

6-K

Foreign Current

TRANSACTION IN OWN SHARES

2026-04-21

Open →

6-K

Foreign Current

DIRECTOR/PDMR SHAREHOLDING

2026-04-20

Open →

6-K

Foreign Current

BLENREP APPROVED IN CHINA FOR 2L+ MULTIPLE MYELOMA

2026-04-20

Open →

6-K

Foreign Current

TRANSACTION IN OWN SHARES

2026-04-20

Open →

6-K

Foreign Current

TRANSACTION IN OWN SHARES

2026-04-17

Open →

6-K

Foreign Current

DIRECTOR/PDMR SHAREHOLDING

2026-04-16

Open →

6-K

Foreign Current

TRANSACTION IN OWN SHARES

2026-04-16

Open →

6-K

Foreign Current

GSK COMPLETES ACQUISITION OF 35PHARMA INC.

2026-04-15

Open →

6-K

Foreign Current

TRANSACTION IN OWN SHARES

2026-04-15

Open →

6-K

Foreign Current

DIRECTOR/PDMR SHAREHOLDING

2026-04-14

Open →

6-K

Foreign Current

TRANSACTION IN OWN SHARES

2026-04-14

Open →

6-K

Foreign Current

DIRECTOR/PDMR SHAREHOLDING

2026-04-13

Open →

6-K

Foreign Current

GSK PRESENTS POSITIVE DATA FOR BEHOLD 1 B7 H4 ADC

2026-04-13

Open →

6-K

Foreign Current

TRANSACTION IN OWN SHARES

2026-04-13

Open →

6-K

Foreign Current

DIRECTOR/PDMR SHAREHOLDING

2026-04-10

Open →

6-K

Foreign Current

TRANSACTION IN OWN SHARES

2026-04-10

Open →

6-K

Foreign Current

DIRECTOR/PDMR SHAREHOLDING

2026-04-09

Open →

6-K

Foreign Current

TRANSACTION IN OWN SHARES

2026-04-09

Open →

6-K

Foreign Current

EXDENSUR APPROVED FOR CRSWNP IN CHINA

2026-04-08

Open →

6-K

Foreign Current

TRANSACTION IN OWN SHARES

2026-04-08

Open →

6-K

Foreign Current

TRANSACTION IN OWN SHARES

2026-04-07

Open →

6-K

Foreign Current

TRANSACTION IN OWN SHARES

2026-04-02

Open →

6-K

Foreign Current

DIRECTOR/PDMR SHAREHOLDING

2026-04-01

Open →

6-K

Foreign Current

TOTAL VOTING RIGHTS

2026-04-01

Open →

6-K

Foreign Current

TRANSACTION IN OWN SHARES

2026-04-01

Open →

6-K

Foreign Current

VIIV COMPLETES CHANGES TO MINORITY SHAREHOLDING

2026-04-01

Open →

6-K

Foreign Current

TRANSACTION IN OWN SHARES

2026-03-31

Open →

6-K

Foreign Current

BEPIROVIRSEN ACCEPTED FOR REVIEW IN CHINA

2026-03-30

Open →

6-K

Foreign Current

EXDENSUR APPROVED FOR SEVERE ASTHMA IN CHINA

2026-03-30

Open →

6-K

Foreign Current

TRANSACTION IN OWN SHARES

2026-03-30

Open →

6-K

Foreign Current

TRANSACTION IN OWN SHARES

2026-03-27

Open →

6-K

Foreign Current

BEPIROVIRSEN ACCEPTED FOR REVIEW BY THE EMA

2026-03-27

Open →

6-K

Foreign Current

TRANSACTION IN OWN SHARES

2026-03-26

Open →

6-K

Foreign Current

DIRECTOR/PDMR SHAREHOLDING

2026-03-25

Open →

6-K

Foreign Current

NOTICE OF AGM

2026-03-25

Open →

6-K

Foreign Current

TRANSACTION IN OWN SHARES

2026-03-25

Open →

6-K

Foreign Current

TRANSACTION IN OWN SHARES

2026-03-24

Open →

6-K

Foreign Current

DIRECTOR/PDMR SHAREHOLDING

2026-03-23

Open →

6-K

Foreign Current

ADMISSION TO TRADING

2026-03-23

Open →

6-K

Foreign Current

GSK LUNG CANCER ADC GETS JAPAN ORPHAN DRUG STATUS

2026-03-23

Open →

6-K

Foreign Current

TRANSACTION IN OWN SHARES

2026-03-23

Open →

6-K

Foreign Current

TRANSACTION IN OWN SHARES

2026-03-20

Open →

6-K

Foreign Current

LYNAVOY (LINERIXIBAT) APPROVED BY US FDA

2026-03-19

Open →

6-K

Foreign Current

TRANSACTION IN OWN SHARES

2026-03-19

Open →

6-K

Foreign Current

DIRECTOR/PDMR SHAREHOLDING

2026-03-18

Open →

6-K

Foreign Current

TRANSACTION IN OWN SHARES

2026-03-18

Open →

6-K

Foreign Current

DIRECTOR/PDMR SHAREHOLDING

2026-03-17

Open →

6-K

Foreign Current

TRANSACTION IN OWN SHARES

2026-03-17

Open →

6-K

Foreign Current

TRANSACTION IN OWN SHARES

2026-03-16

Open →

6-K

Foreign Current

US FDA APPROVES AREXVY FOR ADULTS 18-49 AIR

2026-03-13

Open →

6-K

Foreign Current

TRANSACTION IN OWN SHARES

2026-03-13

Open →

6-K

Foreign Current

DIRECTOR/PDMR SHAREHOLDING

2026-03-12

Open →

6-K

Foreign Current

TRANSACTION IN OWN SHARES

2026-03-12

Open →

6-K

Foreign Current

TRANSACTION IN OWN SHARES

2026-03-11

Open →

6-K

Foreign Current

TRANSACTION IN OWN SHARES

2026-03-10

Open →

6-K

Foreign Current

BOARD COMMITTEE CHANGE

2026-03-09

Open →

6-K

Foreign Current

GSK AND ALFASIGMA AGREE GLOBAL LINERIXIBAT RIGHTS

2026-03-09

Open →

6-K

Foreign Current

TRANSACTION IN OWN SHARES

2026-03-09

Open →

6-K

Foreign Current

FILING OF GSK PLC 2025 ANNUAL REPORT ON FORM 20-F

2026-03-06

Open →

20-F

Foreign Annual

20-F

2026-03-06

Open →

6-K

Foreign Current

TRANSACTION IN OWN SHARES

2026-03-06

Open →

6-K

Foreign Current

GSK PUBLISHES ANNUAL REPORT 2025

2026-03-05

Open →

6-K

Foreign Current

TRANSACTION IN OWN SHARES

2026-03-05

Open →

6-K

Foreign Current

DIRECTOR/PDMR SHAREHOLDING

2026-03-04

Open →

6-K

Foreign Current

TRANSACTION IN OWN SHARES

2026-03-04

Open →

6-K

Foreign Current

GSK COMPLETES ACQUISITION OF RAPT THERAPEUTICS

2026-03-03

Open →

6-K

Foreign Current

TRANSACTION IN OWN SHARES

2026-03-03

Open →

6-K

Foreign Current

TRANSACTION IN OWN SHARES

2026-03-02

Open →

6-K

Foreign Current

TOTAL VOTING RIGHTS

2026-03-02

Open →

6-K

Foreign Current

DIRECTOR/PDMR SHAREHOLDING

2026-02-27

Open →

6-K

Foreign Current

TRANSACTION IN OWN SHARES

2026-02-27

Open →

6-K

Foreign Current

LINERIXIBAT ACCEPTED FOR PRIORITY REVIEW IN CHINA

2026-02-26

Open →

6-K

Foreign Current

BEPIROVIRSEN ACCEPTED FOR JAPAN REGULATORY REVIEW

2026-02-26

Open →

6-K

Foreign Current

TRANSACTION IN OWN SHARES

2026-02-26

Open →

6-K

Foreign Current

DIRECTOR/PDMR SHAREHOLDING

2026-02-25

Open →

6-K

Foreign Current

DIRECTOR/PDMR SHAREHOLDING

2026-02-25

Open →

6-K

Foreign Current

GSK ENTERS AGREEMENT TO ACQUIRE 35PHARMA

2026-02-25

Open →

6-K

Foreign Current

TRANSACTION IN OWN SHARES

2026-02-25

Open →

6-K

Foreign Current

DIRECTOR/PDMR SHAREHOLDING

2026-02-24

Open →

6-K

Foreign Current

TRANSACTION IN OWN SHARES

2026-02-24

Open →

6-K

Foreign Current

TRANSACTION IN OWN SHARES

2026-02-23

Open →

6-K

Foreign Current

DIRECTOR/PDMR SHAREHOLDING

2022-02-11

Open →

6-K

Foreign Current

DIRECTOR/PDMR SHAREHOLDING

2022-02-11

Open →

6-K

Foreign Current

BENLYSTA APPROVED IN CHINA FOR LUPUS NEPHRITIS

2022-02-10

Open →

20-F

Foreign Annual

20-F

2021-03-12

Open →

20-F

Foreign Annual

20-F

2020-03-06

Open →

20-F

Foreign Annual

20-F

2019-03-15

Open →

Other filings (8)
GSK plc (GSK) — Pharmaceutical Preparations | Sera Economics